Jarid1A Antibody (1102542) [Unconjugated]

Western Blot shows lysates of NTera‑2 human testicular embryonic carcinoma cell line. PVDF membrane was probed with 2 µg/ml of Mouse Anti-Human Jarid1A Monoclonal Antibody (Catalog # MAB11705) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for Jarid1A at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Left: Simple Western lane view shows lysates of NTera‑2 human testicular embryonic carcinoma cell line, loaded at 0.75 mg/ml. A specific band was detected for Jarid1A at approximately 191 kDa (as indicated) using both 2 µg/ml and 10 µg/ml of Mouse Anti-Human Jarid1A Monoclonal Antibody (Catalog # MAB11705) followed by HRP-conjugated Goat Anti-Mouse Secondary Antibody (Catalog # 042-205). This experiment was conducted under reducing conditions and using the 66-440kDa separation system. Right: Simple Western electropherogram showing the same Mouse Anti-Human Jarid1A Monoclonal Antibody (Catalog # MAB11705) tested at 2 µg/ml (blue line) and 10 µg/ml (green line) in the NTera‑2 human testicular embryonic carcinoma cell line.

• Reactivity: Hu
• Applications: WB, Simple Western
• Clone: 1102542
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Jarid1A Antibody (1102542) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human Jarid1A/KDM5A
  Lys127-Ser287
  Accession # P29375
• Specificity: Detects recombinant human Jarid1A/KDM5a protein in Direct ELISA.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Simple Western 2-10 ug/mL
  • Western Blot 2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Jarid1A Antibody (1102542) [Unconjugated]

• EC 1.14.11
• EC 1.14.11.-
• EC 1.14.11.67
• Histone demethylase JARID1A
• Jarid1A
• JARID1AJumonji, AT rich interactive domain 1A (RBP2-like)
• Jumonji, AT rich interactive domain 1A (RBBP2-like)
• Jumonji/ARID domain-containing protein 1A
• KDM5A
• lysine (K)-specific demethylase 5A
• RBBP2
• RBBP-2
• RBBP2lysine-specific demethylase 5A
• RBP2
• RBP2retinoblastoma binding protein 2
• Retinoblastoma-binding protein 2jumonji, AT rich interactive domain 1A

Background

Jarid1A (also known as KDM5A) is a protein of approximately 175kDa that belongs to the Jumonji/ARID1 (JARID) protein family. It functions primarily as a lysine demethylase, involved in the regulation of histone H3 lysine 4 (H3K4) demethylation, thereby playing a crucial role in chromatin remodeling and epigenetic regulation. Jarid1A is implicated in multiple biological processes, including cell cycle progression, differentiation, and development. Dysregulation of Jarid1A is associated with various pathologies, particularly its overexpression in several types of cancer, where it contributes to tumorigenesis, cancer cell proliferation, and metastasis. It is also linked to altered gene expression profiles in neurological disorders. The role of Jarid1A in transcriptional regulation highlights its potential as a therapeutic target and biomarker for cancer and other diseases involving epigenetic dysregulation.

1. Harmeyer KM, Facompre ND, Herlyn M, Basu D. JARID1 Histone Demethylases: Emerging Targets in Cancer. Trends Cancer. 2017 Oct;3(10):713-725. doi: 10.1016/j.trecan.2017.08.004. Epub 2017 Sep 12. PMID: 28958389; PMCID: PMC5679451. 
2. Yang GJ, Zhu MH, Lu XJ, Liu YJ, Lu JF, Leung CH, Ma DL, Chen J. The emerging role of KDM5A in human cancer. J Hematol Oncol. 2021 Feb 17;14(1):30. doi: 10.1186/s13045-021-01041-1. PMID: 33596982; PMCID: PMC7888121.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P29375(Mouse)